BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 6499356)

  • 1. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
    Wedlund PJ; Aslanian WS; McAllister CB; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1984 Dec; 36(6):773-80. PubMed ID: 6499356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
    Nakamura K; Goto F; Ray WA; McAllister CB; Jacqz E; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.
    Küpfer A; Preisig R
    Eur J Clin Pharmacol; 1984; 26(6):753-9. PubMed ID: 6489416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.
    Inaba T; Jurima M; Nakano M; Kalow W
    Clin Pharmacol Ther; 1984 Nov; 36(5):670-6. PubMed ID: 6488688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians.
    Kiivet RA; Svensson JO; Bertilsson L; Sjöqvist F
    Pharmacol Toxicol; 1993 Feb; 72(2):113-5. PubMed ID: 8474964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotyping polymorphic drug metabolism in the French Caucasian population.
    Jacqz E; Dulac H; Mathieu H
    Eur J Clin Pharmacol; 1988; 35(2):167-71. PubMed ID: 3191936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo.
    Sanz EJ; Bertilsson L
    Ther Drug Monit; 1990 May; 12(3):297-9. PubMed ID: 2349617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests.
    Spina E; Buemi AL; Sanz E; Bertilsson L
    Ther Drug Monit; 1989 Nov; 11(6):721-3. PubMed ID: 2595755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphic debrisoquine and mephenytoin hydroxylation in patients with pulmonary hypertension of vascular origin after aminorex fumarate.
    Saner H; Gurtner HP; Preisig R; Küpfer A
    Eur J Clin Pharmacol; 1986; 31(4):437-42. PubMed ID: 3816924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin.
    Baumann P; Jonzier-Perey M; Koeb L; Küpfer A; Tinguely D; Schöpf J
    Int Clin Psychopharmacol; 1986 Apr; 1(2):102-12. PubMed ID: 3571939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.
    Jurima M; Inaba T; Kadar D; Kalow W
    Br J Clin Pharmacol; 1985 Apr; 19(4):483-7. PubMed ID: 3994895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation.
    Küpfer A; Branch RA
    Clin Pharmacol Ther; 1985 Oct; 38(4):414-8. PubMed ID: 4042524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Family studies of mephenytoin hydroxylation deficiency.
    Inaba T; Jurima M; Kalow W
    Am J Hum Genet; 1986 May; 38(5):768-72. PubMed ID: 3717162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine.
    Atiba JO; Blaschke TF; Wilkinson GR
    Br J Clin Pharmacol; 1989 Aug; 28(2):161-5. PubMed ID: 2775621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo.
    Meier UT; Dayer P; Malè PJ; Kronbach T; Meyer UA
    Clin Pharmacol Ther; 1985 Nov; 38(5):488-94. PubMed ID: 4053486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphism of mephenytoin metabolism.
    Inaba T
    Prog Clin Biol Res; 1986; 214():139-56. PubMed ID: 3523505
    [No Abstract]   [Full Text] [Related]  

  • 17. Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital.
    Jacqz E; Hall SD; Branch RA; Wilkinson GR
    Clin Pharmacol Ther; 1986 Jun; 39(6):646-53. PubMed ID: 3709029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mephenytoin hydroxylation in the Cuna Amerindians of Panama.
    Inaba T; Jorge LF; Arias TD
    Br J Clin Pharmacol; 1988 Jan; 25(1):75-9. PubMed ID: 3370193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.
    Dahl-Puustinen ML; Alm C; Bertilsson L; Christenson I; Ostman J; Thunberg E; Wikström I
    Br J Clin Pharmacol; 1990 Sep; 30(3):476-80. PubMed ID: 2121211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.
    Bertilsson L; Lou YQ; Du YL; Liu Y; Kuang TY; Liao XM; Wang KY; Reviriego J; Iselius L; Sjöqvist F
    Clin Pharmacol Ther; 1992 Apr; 51(4):388-97. PubMed ID: 1345344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.